We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Alternative Molybdenum Source Could Surmount Isotope Shortage

By HospiMedica International staff writers
Posted on 03 Jan 2016
New technology for manufacturing molybdenum-99 (99Mo) without the need for a nuclear reactor could help break through the medical isotope bottleneck.

Developed by SHINE Medical Technologies (SHINE; Monona, WI, USA), the alternative production method involves bombarding a low enriched uranium (LEU) uranyl sulfate solution with fast neutrons generated by a linear accelerator at Argonne National Laboratory (ANL; Lemont, IL, USA). More...
The LEU then breaks down into hundreds of different isotopes, including 99Mo, which consists of 6% of the fissions created during the process. The 99Mo, which has a half-life of 2.75 days, must then be separated from the other fission products before it can be transported for use.

The half life of 99Mo is long compared to that of its daughter isotope, the radioactive tracer element technetium-99m (99mTc), which is created when 99Mo spontaneously decays through the release of a beta particle from its nucleus. The 99mTc, whose half-life is just six hours, is crucial for the sodium pertechnetate tracer produced using the GE Healthcare (GE, Little Chalfont, United Kingdom) Drytec generator. GE tested the new method by preparing two 99mTc-based radiopharmaceuticals, indicating the feasibility of the production method.

“We have been confident from the beginning that molybdenum-99 produced by our process would be compatible with existing technetium-99m generators, and now we’ve proved it,” said Greg Piefer, CEO of SHINE. “This demonstration validates that the cleaner, safer technical approach we’ve been pursuing can be fully integrated into the existing supply chain. I would like to thank GE and Argonne National Laboratory for making this test possible.”

“Our customers—clinics, hospitals and imaging specialists—rely on a secure supply of technetium-99m from molybdenum-99 to make sure that they can conduct important diagnostic imaging scans their patients need,” said Jan Makela, general manager of core imaging for GE Healthcare. “We are working hard to make this key isotope readily available and cost-effective for them.”

Because of its unstable nature, 99Mo does not occur naturally and is traditionally produced using highly enriched uranium (HEU) in research reactors. 99Mo is also not produced in the United States, leaving the country to rely on isotopes from other countries. SHINE is expected to begin commercial production in 2019 using this new process, and expects to be able to produce enough 99Mo to supply two-thirds of the demand of the United States.

Related Links:

SHINE Medical Technologies
Argonne National Laboratory
GE Healthcare



Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Temperature Monitor
ThermoScan Temperature Monitoring Unit
Medical Monitor
SILENIO D
Gold Member
Electrode Solution and Skin Prep
Signaspray
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.